The use of dual antiplatelet therapy (DAPT) after stent implantation in a percutaneous coronary intervention (PCI) is the standard treatment. The first randomised controlled trial (RCT) to establish the superiority of DAPT versus oral anticoagulant treatment among patients undergoing PCI was the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial, published in 1996. 1 Since then, more than 35 RCTs have been carried out, with more than 225,000 participants, to assess different aspects of DAPT in this context, including the ideal approach of antiplatelet drug and the optimal duration of treatment.
the duration of DAPT in patients with coronary artery disease (CAD). 10 These guidelines were developed based on the results of a systematic review of all the studies carried out on this topic. 11 More recently, the European Society of Cardiology (ESC), in collaboration with the European Association of Cardiothoracic Surgery, published an update of the guidelines on DAPT in CAD. 12 Both documents show a high degree of consensus, but in this article we will focus on the recommendations in the European guidelines.
Since the publication of these two practice guidelines, several studies have been published which address similar questions and many others are in the inclusion or follow-up phase and the findings will probably have an impact on future guidelines. We will, therefore, comment on some of these most interesting studies.
The clinical context in which the patient is being treated must always be considered when making a decision about the type of antiplatelet drug and the duration of treatment, so we will discuss patients undergoing percutaneous revascularisation in a stable situation separately from those revascularised in the setting of ACS. Moreover, the management of patients undergoing percutaneous revascularisation who also have a high risk of bleeding or need chronic oral anticoagulation require a separate mention.
DAPT After Percutaneous Revascularisation in Stable Coronary Artery Disease
There are no clinical trials that assess the duration of DAPT exclusively in stable patients, so all the recommendations have been drawn from subgroups from wider trials. There is also a lack of trials that evaluate the use of prasugrel or ticagrelor as an alternative to clopidogrel in the stable context, although their use is accepted in selected patients who have unsatisfactory previous use or clinical resistance to clopidogrel, drug allergy or a high risk of ischaemia.
DAPT for at Least 12 Months Versus 3-6 Months
Several trials have aimed to assess this aspect, all with very similar results, and have led to the proposed recommendations.
The Efficacy of Xience/promus versus Cypher in rEducing Late
Loss after stENTing (EXCELLENT) compared a strategy of 6 months versus 12 months of DAPT (ASA and clopidogrel). 13 It included 1, 443 patients treated with DES. At 1 year, the 12-month group had a target These studies show that maintaining long-term DAPT in patients with stable CAD treated with DES confers a benefit in terms of secondary prevention of ischaemic events and reduction of stent thrombosis, but at the expense of an increased risk of bleeding and a potential increase in global mortality.
Taking all this into account, the class I level A recommendation is that maintenance of DAPT is not systematically recommended beyond 6 months and the duration should be individualised according to the patient's risk profile. It will be necessary to assess the patient's ischaemic and bleeding risk in the medium to long term, for which several tools have been developed. Those recommended in the European guidelines are the PRECISE-DAPT score and the DAPT score.
The PRECISE-DAPT score decides the duration of DAPT at the time of stent implantation. 24 The DAPT score can be used to make decisions to prolong DAPT after an uneventful first year post-PCI. Of note, the type of stent implanted is important when assessing the benefit of extending DAPT beyond one year. This benefit is clearer in patients with firstgeneration DES, although these are no longer used.
There have been no studies assessing the optimal duration of DAPT after implantation of bioabsorbable scaffolds, but there is evidence of an increased risk of stent thrombosis in the first month and in the long term, which is why, in patients treated with these stents, it seems reasonable to recommend DAPT for at least 12 months, and even prolong it when the risk of bleeding is low.
DAPT After Percutaneous Revascularisation in Acute Coronary Syndrome
The usefulness of DAPT with ASA and clopidogrel for 1 year in patients with ACS has been amply demonstrated. 8, 9 There are also studies that versus clopidogrel in this context. 25, 26 Although both prasugrel and ticagrelor significantly increase the risk of major TIMI bleeding not related to surgery, the risk-benefit ratios are favourable, with a number needed to treat to prevent a primary outcome of 46 and 53, respectively, and the number needed to harm of 167 for both drugs.
For these reasons, the recommendation is to prescribe DAPT for 1 year after ACS has been established, preferably with ticagrelor or prasugrel, unless there are contraindications (class I level C).
DAPT for 12 Months Versus 3-6 Months
Following the idea that longer DAPT exposes the patient to higher bleeding risk and therefore poorer prognosis and in line with the studies that seek to shorten the duration of DAPT in stable patients, a line of research is also arising in the setting of ACS.
The Dual Antiplatelet Therapy after drug-eluting stent implantation in ST-elevation MI (DAPT-STEMI) trial was designed to show that limiting DAPT to 6 months in patients with event-free ST-elevation MI (STEMI) results in a non-inferior clinical outcome (composite of all-cause mortality, any MI, any revascularisation, stroke and TIMI major bleeding at 18 months after randomisation) versus DAPT for 12 months. 27 There were 1,100 patients enrolled. The authors concluded that the shortterm strategy was non-inferior in the long term in patients with eventfree STEMI at 6 months after primary PCI with second generation DES.
A later meta-analysis included 17,941 patients from three RCTs and eight RCT sub-analysis allocated to two groups according to the DAPT strategy. It concluded that a short duration of DAPT may be safely considered, with similar rates of recurrent thrombotic complications compared with the standard 12 months, and similar mortality. 28 After this meta-analysis was published, new data have been released showed that short-duration DAPT (3 months) followed by P2Y 12 inhibitor monotherapy is non-inferior to longer-duration DAPT (12 months) among unselected patients undergoing PCI with a DES. 30 The results of all the above-mentioned studies were published after the ESC guidelines were published. Therefore, no specific mention on this strategy is made apart from the 6 months recommendation in patients at high risk of bleeding.
DAPT for 12 Months Versus More Than 12 Months
Patients with ACS have a high cardiovascular risk beyond the first year and intensive DAPT has been shown to be effective in reducing the rate of new recurrent ischaemic events. The risk-benefit balance is not so clear and several trials have been developed to try to clarify the issue.
The Prevention of Cardiovascular Events in Patients with Prior Heart
Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) study included 21,162 patients with a previous MI (between 1 and 3 years before the start of the study) and a high-risk profile.
Monotherapy with ASA was compared with two DAPT regimens with ASA and ticagrelor (60 mg or 90 mg). Although the main combined result of efficacy (cardiovascular death, MI and stroke at 3 years) was significantly better in the ticagrelor groups (7.85% with 90 mg and 7.77% with 60 mg versus 9.04% in ASA monotherapy), a significant increase in TIMI bleeding was also observed (2.6% with 90 mg, 2.3% with 60 mg and 1.06% in ASA monotherapy). Therefore, it is not possible to obtain a net benefit with 90 mg ticagrelor and the benefits are marginal with 60 mg ticagrelor. 31 For these reasons, the generalised use of DAPT with ASA and ticagrelor beyond a year after an ACS is discouraged and more individualised use is advocated, considering the ischaemic and haemorrhagic risks of each particular patient. Recently, a meta-analysis including clinical trials that assess the use of DAPT (clopidogrel, prasugrel or ticagrelor) beyond 12 months after ACS has been carried out. The conclusions are similar: reduction in cardiovascular events at the expense of an increase in bleeding with neutral or negative impact on overall mortality. 32 Although these findings seem to show a consistent class effect among the three P2Y 12 receptor inhibitors, the use of 60 mg ticagrelor is recommended in patients with a low risk of bleeding in whom it is decided to continue with DAPT after 1 year. This recommendation is based on the fact that ticagrelor is the most widely studied drug and has the most complete trials.
DAPT Duration in Patients with a High Risk of Bleeding
The In this study, 2,466 patients with medium-high or high bleeding risk were randomised to BioFreedom (polymer-free DES) or BMS with a 1-month DAPT in both cases. The BioFreedom stent arm was better in terms of safety and efficacy. A class IIb recommendation has been made for 1-month DAPT linked to this stent.
Therefore, the ESC guidelines suggest that the withdrawal of DAPT after 3 months in stable patients (class IIa level B) and after 6 months in ACS patients (class IIa level C) in the presence of a high bleeding risk could be considered. The reduction of DAPT to 1 month could be considered in stable cases with increased bleeding risk, but it should be linked to the use of the above-mentioned stent.
A tool that could aid decision making regarding DAPT duration after PCI would be useful and the PRECISE-DAPT score might play a key role.
After the input of five simple items, it gives the likelihood of the patient's out-of-hospital bleeding risk. A cutoff value of >25 could identify those patients at higher risk of bleeding. 24 There are several ongoing trials examining the safety of very short-term 
Role of De-escalation in DAPT
The risk of ischaemic complications is most likely just after PCI and the risk gradually decreases. The same happens after an ACS. Hence, the hypothesis that, during the chronic phase, once the disease stabilises, the level of platelet anti-aggregation required might be lower than in the acute phase. The following trials tested this hypothesis.
The Testing Responsiveness to Platelet Inhibition on Chronic
Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trial studied patients undergoing PCI after ACS. After 1 week of DAPT with prasugrel and ASA, the participants were randomised to prasugrel or clopidogrel for 12 months. The results of a subsequent platelet aggregation test were used to guide the therapy in the latter group. The results indicate non-inferiority of the de-escalation therapy compared with maintenance therapy. 36 The Timing of Platelet Inhibition after Acute Coronary Syndrome (TOPIC) trial involved 645 patients who had a PCI following an ACS, and after an uneventful 1-month period of ASA and a newer P2Y 12 , were randomised to continue their DAPT regimen or switch to ASA and clopidogrel. After 1 year of follow-up, there were a similar amount of ischaemic events in both groups, with a significant reduction in bleeding complications in the de-escalation group. 37 Information on how to de-escalate (switching from prasugrel or ticagrelor to clopidogrel) is found in the 2017 ESC guidelines and in the international expert consensus on switching platelet P2Y 12 receptorinhibiting therapies. 12, 38 Acetylsalicylic Acid-free Strategy
There is a growing feeling that the era of lifelong ASA treatment might be over, and some studies are trying to assess this topic.
The goal of the Clinical Study Comparing Two Forms of Anti-platelet
Therapy After Stent Implantation (GLOBAL-LEADERS) trial was to evaluate 1 month of aspirin plus ticagrelor followed by 23 months of ticagrelor monotherapy compared with 1 year of dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor) followed by 1 year of aspirin monotherapy among 15,968 patients undergoing PCI with a BES. The composite outcome, components of the primary outcome and major bleeding were similar between treatment groups. The experimental strategy of a shorter duration of DAPT did not increase ischaemic events. 39 The goal of the Short and Optimal Duration of Dual Antiplatelet Therapy
After Everolimus-Eluting Cobalt-Chromium Stent-2 (STOPDAPT-2) trial was to evaluate 1 month of DAPT compared with 12 months of DAPT among patients undergoing PCI in stable and unstable settings) with a cobalt chromium everolimus-eluting stent. 40 The 3,045 participants were randomised to either 1 month of DAPT followed by clopidogrel monotherapy for 5 years or 12 months of DAPT followed by aspirin monotherapy for 5 years. The authors concluded that 1 month of DAPT followed by clopidogrel monotherapy was superior to 12 months of DAPT followed by aspirin monotherapy at preventing net adverse clinical events (non-inferior at preventing ischaemic events and superior at preventing bleeding).
The SMART-CHOICE trial is also aligned with this 'off-ASA' strategy.
Other ongoing trials are also assessing ASA-free strategies -Ticagrelor 
DAPT in Patients with Indication for Oral Anticoagulation
It is estimated that about 6-8% of patients who undergo PCI also There are a number of considerations that must be acknowledged to decide the most appropriate approach for these patients.
Type of Antiplatelet Treatment
There are no trials that have assessed the efficacy or safety of triple therapy (DAPT and OAC) with prasugrel or ticagrelor, but there are worrying data showing increased bleeding in various registries. Therefore, it is recommended to avoid ticagrelor and prasugrel in triple therapy.
Duration of Triple Therapy and Triple Versus Dual Therapy
The following trials have evaluated the duration of triple therapy and triple versus dual therapy.
The What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) trial saw 573 patients randomised after PCI to dual therapy with clopidogrel and OAC versus triple therapy with ASA, clopidogrel and OAC for 1 or 12 months (depending on the use of BMS or DES). The dual therapy arm showed a significant reduction in total bleeding and overall mortality without differences in major bleeding or cardiovascular events. 41 The Neither of these studies has sufficient power to assess significant differences in the rate of ischaemic events (stroke or thrombosis).
The Triple Therapy in Patients on Oral Anticoagulation after Drug Eluting
Stent Implantation (ISAR-TRIPLE) included 614 patients undergoing PCI receiving OAC. 43 They were randomised to receive triple therapy (ASA, clopidogrel and VKA) for 6 weeks or 6 months. There were no significant differences between groups in any aspect.
These three studies consistently show that the rate of bleeding peaks a month after the start of triple therapy and that the rate of haemorrhagic events doubles that of coronary ischaemic events (infarction or thrombosis).
The The authors found a significant decrease in haemorrhagic events in the two dual therapy arms compared with triple therapy while maintaining safety (not inferiority to VKA). 44 A meta-analysis including the four trials mentioned above compared the safety and efficacy of dual versus triple antithrombotic therapy in patients on OAC secondary to AF undergoing PCI. A total of 5,317
patients were included. The study concludes that the dual therapy showed a 47% reduction in TIMI major or minor bleeding with comparable outcomes for MACE. 45 The regimen (VKA-based) or dual antithrombotic therapy with 60 mg edoxaban and a P2Y 12 inhibitor. The edoxaban-based dual antithrombotic therapy was non-inferior for bleeding compared with VKA-based triple antithrombotic regimen, without significant differences in ischaemic events.
The ESC guidelines propose two strategies that are selected based on the balance of ischaemic and haemorrhagic risks:
• Triple therapy with ASA, clopidogrel and OAC for 1 month, extendable to 6 months in patients with higher ischaemic risk and lower risk of bleeding.
• Dual therapy with clopidogrel and OAC from the beginning in cases of higher bleeding risk and lower ischaemic risk.
However, the results of REDUAL-PCI and AUGUSTUS trials were known after the publication of the guidelines, and these, along with the other studies mentioned above, seem to suggest the end the use of triple therapy for patients with non-valvular AF undergoing PCI.
The 2018 North American Perspective Update on antithrombotic therapy in patients undergoing PCI recommends a shorter (only periprocedural) period of triple therapy in most settings. 48 Definitive Suspension of Antiplatelet Therapy Due to an insufficient sample size (696 patients), the noninferiority goal was not established. However, the International Society of Thrombosis and Haemostasis stated that major bleeding was lower in the only OAC group, suggesting that OAC alone might be reasonable for patients with AF beyond 1 year after coronary stenting. 49 Dual therapy with an antiplatelet drug and an OAC is limited for patients who meet some criterion which indicate they have a high risk of ischaemia, such as previous stent thrombosis, PCI of the only permeable coronary artery, diabetes with diffuse coronary disease, renal insufficiency, more than three stents implanted, more than three lesions treated, bifurcation treated with two stents technique, total length of stent >60 mm or treatment of a chronic occlusion.
Type of Stent
The choice of a new generation DES over a BMS in patients with OAC indication is well established.
We have developed an algorithm at the Hospital Universitario Marqués de Valdecilla that we propose as a tool to help decide the duration of DAPT after PCI (Figures 1 and 2) .
There are two different algorithms depending on the need of chronic anticoagulation. The protocols consider the bleeding risk assessed with the PRECISE-DAPT score and the presence of certain comorbidities as well as the ischaemic risk assessed with the clinical presentation and the PCI complexity. We consider a PCI to be complex when at least one of the following is present:
• PCI over three vessels.
• The use of more than three stents.
• A two-stent strategy in a bifurcation
• Total length of stent >60 mm.
• The treatment of a chronic total occlusion.
The different colours for time durations are roughly related to the level of evidence supporting the indication. It is designed to guide the clinician in the final decision, and it is meant to be thought of as a continuum.
Conclusion
PCI has evolved dramatically in recent years and it has changed the approach in the management of ischaemic heart disease. This has been due to the development of new devices and antithrombotic therapies. We have reviewed the indications and modalities of antiaggregant-anticoagulant therapy after PCI in different scenarios.
The multiple trials carried out have modified the approach of this therapy from a routine general approach that did not consider individual variables of the patients to a more comprehensive approach that takes into account the balance of ischaemic-thrombotic and haemorrhagic risks, informed from patient variables, coronary heart disease symptoms and features of the PCI procedure.
